Myelofibrosis Facts Quiz
Quiz

Myelofibrosis Facts Quiz

1 out of 0

This online assesment takes only 2 minutes. It will help you find the right clinical trials for you.

A gene mutation in the Janus kinase 2 (JAK2) gene is common in myelofibrosis cases and can help determine prognosis and treatment.
Ruxolitinib is a medicine that is a kinase inhibitor, used to treat myelofibrosis with the JAK2 genetic mutation.
Currently, allogeneic hematopoietic cell transplant (HCT) is the only chance for a cure, however it is not an option for most patients.
Fedratinib is a medicine that is called a kinase inhibitor. It targets the JAK2 genetic mutation commonly detected in myelofibrosis patients.
Anemia is very uncommon in myelofibrosis patients.

Almost Done!

Please complete the required fields and we will send results to your email.


    Your personal data is fully confidential and 100% secure

    You have completed the quiz.

    0 out 0 answers are correct

    The Quiz Results
    Why are we asking this?

    We ask this to determine which clinical trials you may be eligible for.

    Samantha Kingsbery Massive Bio Clinical Nurse

    If you need to contact us right away?

    Call +1 844 627 7246

    Your personal data is fully confidential and 100% secure

    Join our community
    and receive our newsletter